Search results
Showing 6916 to 6930 of 8314 results
Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.
Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)
This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.
Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)
April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.
November 2024: This evidence summary has been withdrawn because licensed products are now available.
Daylight for treating generalised anxiety disorder in adults (MIB309)
August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.
Ventripoint Medical System Plus for measuring heart volume and function (MIB310)
February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.
This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
BPMpathway for rehabilitation support in joint replacement surgery (MIB319)
MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.
Flow transcranial direct current stimulation for treating depression (MIB324)
May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.
Four commonly used methods to increase physical activity (PH2)
This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41 Physical activity: brief advice for adults in primary care (2013) PH44 Exercise referral schemes to promote physical activity (2014) PH54
The recommendations in this guideline on weight management during pregnancy have been updated and replaced by NICE's guideline on maternal and child nutrition (NG247). The recommendations on weight management before and after pregnancy have been updated and replaced by NICE’s guideline on overweight and obesity management (NG246).
January 2025: This quality standard has been stood down. Quality statements on maternal and child nutrition can be found in the NICE quality standards on antenatal care and postnatal care.
This guideline has been updated and replaced by NICE guideline NG101.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.